deferasirox
Generic: DEFERASIROX·Brand: DEFERASIROX, EXJADE, JADENU, JADENU SPRINKLE, Jadenu
deferasirox: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
deferasirox evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
Source-backed records connect deferasirox to NVS; that link alone does not prove the drug works.
What to watch
Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected
Prepared research question
How could deferasirox → NVS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| Novartis AG (NVS) | Approved |
| Novartis AG (NVS) | Approved |
Clinical Trials (1)
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Primary endpoint: Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis
InterventionalRandomizedquadruple20 enrolledStarted 2007-10Completion 2010-127 sites · United StatesLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
FDA Decisions1 records
Frequently asked questions
Who is developing deferasirox?
deferasirox is being developed by Novartis AG.
How many clinical trials involve deferasirox?
BioSniper tracks 1 clinical trial involving deferasirox.
What is deferasirox's latest FDA decision?
The most recent tracked FDA decision for deferasirox is Approval, dated May 18, 2017.